|
RNF20 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.27200505473502E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.17429999058061E-09 |
| Normal-vs-Stage2 |
1.363250E-03 |
| Normal-vs-Stage3 |
6.29463148271725E-12 |
| Normal-vs-Stage4 |
1.17750031947139E-10 |
| Stage1-vs-Stage2 |
1.495350E-01 |
| Stage1-vs-Stage3 |
2.907900E-02 |
| Stage1-vs-Stage4 |
4.723900E-03 |
| Stage2-vs-Stage3 |
4.779500E-03 |
| Stage2-vs-Stage4 |
2.256300E-03 |
| Stage3-vs-Stage4 |
4.126800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.16002779499058E-12 |
| Normal-vs-AfricanAmerican |
2.241400E-03 |
| Normal-vs-Asian |
6.30680000002215E-07 |
| Caucasian-vs-AfricanAmerican |
2.563800E-01 |
| Caucasian-vs-Asian |
6.565200E-01 |
| AfricanAmerican-vs-Asian |
4.472600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.57339951967606E-10 |
| Normal-vs-Female |
3.2988944909107E-11 |
| Male-vs-Female |
2.968400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.29019999923253E-09 |
| Normal-vs-Age(41-60Yrs) |
5.70410052525006E-10 |
| Normal-vs-Age(61-80Yrs) |
1.39940004029171E-09 |
| Normal-vs-Age(81-100Yrs) |
3.555700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.938600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.444200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.452580E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.267400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.742750E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.481200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.218310E-02 |
| Classical-VS-Follicular |
8.409000E-01 |
| Classical-VS-Other |
4.047800E-01 |
| Classical-VS-Normal |
2.58160048893785E-10 |
| Tall-VS-Follicular |
1.870410E-02 |
| Tall-VS-Other |
6.459200E-01 |
| Tall-VS-Normal |
6.26280027837822E-10 |
| Follicular-VS-Other |
5.187400E-01 |
| Follicular-VS-Normal |
8.9246000001264E-07 |
| Other-VS-Normal |
6.175800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.57649998505849E-09 |
| Normal-vs-N1 |
3.43960415705169E-11 |
| N0-vs-N1 |
2.719100E-03 |
|
|
